Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | gamma-aminobutyric acid (GABA) A receptor, alpha 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Neurotransmitter-gated ion-channel ligand binding domain containing protein | gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 451 aa | 393 aa | 25.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | TK/EGFR protein kinase | 0.0334 | 0.0886 | 0.0886 |
Trichomonas vaginalis | calcium binding protein, putative | 0.0048 | 0 | 0.5 |
Giardia lamblia | Programmed cell death protein-like protein | 0.0048 | 0 | 0.5 |
Loa Loa (eye worm) | TK/INSR protein kinase | 0.0107 | 0.0182 | 0.0182 |
Loa Loa (eye worm) | hypothetical protein | 0.1235 | 0.3683 | 0.3683 |
Toxoplasma gondii | EF hand domain-containing protein | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0179 | 0.0407 | 0.4595 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.0334 | 0.0886 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0107 | 0.0182 | 0.0182 |
Echinococcus granulosus | insulin receptor | 0.0107 | 0.0182 | 0.2051 |
Echinococcus granulosus | epidermal growth factor receptor | 0.0334 | 0.0886 | 1 |
Echinococcus granulosus | melanoma receptor tyrosine protein kinase | 0.0179 | 0.0407 | 0.4595 |
Schistosoma mansoni | tyrosine kinase | 0.0177 | 0.0401 | 0.3117 |
Toxoplasma gondii | calmodulin, putative | 0.0048 | 0 | 0.5 |
Toxoplasma gondii | calcium binding protein precursor, putative | 0.0048 | 0 | 0.5 |
Onchocerca volvulus | Dual oxidase homolog | 0.327 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0177 | 0.0401 | 0.3117 |
Echinococcus granulosus | insulin growth factor 1 receptor beta | 0.0107 | 0.0182 | 0.2051 |
Schistosoma mansoni | tyrosine kinase | 0.0177 | 0.0401 | 0.3117 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.2035 | 0.6168 | 0.5 |
Echinococcus multilocularis | insulin receptor | 0.0107 | 0.0182 | 0.2051 |
Trichomonas vaginalis | caltractin, putative | 0.0048 | 0 | 0.5 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.2035 | 0.6168 | 0.5 |
Trichomonas vaginalis | caltractin, putative | 0.0048 | 0 | 0.5 |
Plasmodium falciparum | centrin-4 | 0.0048 | 0 | 0.5 |
Echinococcus granulosus | epidermal growth factor receptor | 0.0179 | 0.0407 | 0.4595 |
Schistosoma mansoni | tyrosine kinase | 0.0334 | 0.0886 | 1 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.0107 | 0.0182 | 0.2051 |
Brugia malayi | Furin-like cysteine rich region family protein | 0.0334 | 0.0886 | 0.0886 |
Entamoeba histolytica | hypothetical protein | 0.0581 | 0.1655 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0179 | 0.0407 | 0.32 |
Echinococcus multilocularis | 0.0103 | 0.0171 | 0.1934 | |
Schistosoma mansoni | tyrosine kinase | 0.0179 | 0.0407 | 0.32 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.2035 | 0.6168 | 0.5 |
Leishmania major | ferric reductase, putative | 0.2035 | 0.6168 | 0.5 |
Treponema pallidum | hypothetical protein | 0.0581 | 0.1655 | 0.5 |
Loa Loa (eye worm) | blistered cuticle protein 3 | 0.327 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 3100 nM | Inhibition of [3H]-EBOB binding at GABA-gated chloride channel NCB site in bovine brain membranes | ChEMBL. | No reference |
IC50 (binding) | = 3100 nM | Inhibition of [3H]-EBOB binding at GABA-gated chloride channel NCB site in bovine brain membranes | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.